Virpax Pharmaceuticals, Inc. financial data

Symbol
VRPX on Nasdaq
Location
1055 Westlakes Drive, Suite 300, Berwyn, PA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 3, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 52.1 % -80.7%
Debt-to-equity -209 % -454%
Return On Assets -637 % -499%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 26.6M shares +2168%
Common Stock, Shares, Outstanding 14.9M shares +1171%
Entity Public Float 1.47M USD -84.4%
Common Stock, Value, Issued 149 USD +1142%
Weighted Average Number of Shares Outstanding, Basic 4.25M shares +263%
Weighted Average Number of Shares Outstanding, Diluted 4.25M shares +263%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 5.82M USD +13.7%
General and Administrative Expense 6.26M USD -40.8%
Operating Income (Loss) -12.1M USD +23%
Nonoperating Income (Expense) 8.13K USD -93.6%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -16.9M USD +6.35%
Net Income (Loss) Attributable to Parent -12.1M USD +20.6%
Earnings Per Share, Basic -2.84 USD/shares +78.1%
Earnings Per Share, Diluted -2.84 USD/shares +78.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current 1.56M USD -83.8%
Assets 1.56M USD -83.8%
Liabilities, Current 2.47M USD -67.9%
Liabilities 2.47M USD -67.9%
Retained Earnings (Accumulated Deficit) -71.6M USD -20.3%
Stockholders' Equity Attributable to Parent -914K USD -147%
Liabilities and Equity 1.56M USD -83.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.73M USD -285%
Net Cash Provided by (Used in) Financing Activities 454K USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 14.9M shares +1171%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.51M USD -83.4%
Deferred Tax Assets, Valuation Allowance 18.3M USD +15.3%
Deferred Tax Assets, Gross 18.3M USD +15.3%
Deferred Tax Assets, Operating Loss Carryforwards 12.5M USD +41%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 70.7M USD +15%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 135K USD -75.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%